The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Examining the Role of LRRK2 and Glucocerebrosidase Dysfunction in Exosome-mediated Release of the Lipid Biomarker Bis(monocylglycero)phosphate in Parkinson's Disease
Study Rationale: Mutations in LRRK2 and GBA1 (which encodes the enzyme glucocerebrosidase, or GCase) are among the most common genetic risk factors for Parkinson’s disease (PD). Individuals with these...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Characterization of a Novel Strategy to Target LRRK2 and Its Downstream Signaling Pathway
Study Rationale: Genetic mutations that activate LRRK2 are linked to familial Parkinson’s disease (PD). However, no clinically approved inhibitors for LRRK2 currently exist. In this study, we will...
-
ASAP, 2023(SUPPLEMENT) Examining How Genes and Gut Bacteria Cooperate to Cause Parkinson’s Disease
Study Rationale: Recent studies suggest that the alpha-synuclein protein that forms aggregates in Parkinson’s disease (PD) may originate in the gut and travel along nerves that go to the brain...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Investigating the Molecular Basis of Neurodegeneration in GBA-associated Parkinson's Disease
Study Rationale: Mutations in GBA1, the gene that encodes the enzyme glucocerebrosidase (GCase), are among the most common genetic risk factor for the development of Parkinson’s disease (PD). GCase...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Discovering Ocular Biomarkers of Parkinson’s Disease
Study Rationale: Early detection of Parksinson’s disease (PD) leads to improved care and better quality of life. However, the current methods for diagnosing PD, physical examination and brain imaging...
-
Lysosomal Biomarkers Program, 2023Development of Autophagy-lysosome Biomarkers for Parkinson’s Disease Using Stem Cell-derived Neurons and Biofluids
Study Rationale: Genetic, molecular, and pathological studies have highlighted the role of dysfunctional mechanisms for clearing cellular debris — called autophagy-lysosome pathways — in the...
![Two female doctors talking in the lab.](/sites/default/files/styles/ad_callout_single/public/images/ad/apply-for-grant-404-Large-Image-Callout-A-1.jpg?h=2a1ad497&itok=-_5jZ5iX)
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.